# **RIQAS**

### RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

ENROLMENT DOCUMENT COAGULATION PROGRAMME RQ9135

This document must be completed and returned to  $\ensuremath{\mathsf{RIQAS}}$ 

# **RIQAS**

# **COAGULATION PROGRAMME**

### **RQ9135**

| Lab. Reference Number  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|
| Please tick the correct option: This is a new registration for Coagulation |  |  |  |  |  |  |
| This is an update to an existing Coagulation registration                  |  |  |  |  |  |  |
| ease complete separate enrolment d   | ocuments for each instrument   |  |  |  |  |  |
| nt identification name here  |  |  |  |  |  |  |
| ontact RIQAS or your local Randox office or distrib                        | outor for more details.  |  |  |  |  |  |
| S directly.  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| elow   |  |  |  |  |  |  |
| Cycle 17   | January 2025 - December 2025   |  |  |  |  |  |
|  | 12 months  |  |  |  |  |  |
| nly: PT, aPTT, TT, Fibrinogen, Anti-throi                                  | mbin III)  |  |  |  |  |  |
| choose from 16)  |  |  |  |  |  |  |
| RS ONLY)   |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| State  |  |  |  |  |  |  |
| ,  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  | This is a new registration for Coar This is an update to an existing Coarease complete separate enrolment of the identification name here  Intact RIQAS or your local Randox office or distributed and interesting the identification of the identification name here  Cycle 17  Cycle 17  Inly: PT, aPTT, TT, Fibrinogen, Anti-through choose from 16)  RS ONLY)  State |  |  |  |  |  |

| Lab. Reference Number |  |
|-----------------------|--|
|-----------------------|--|

#### RIQAS COAGULATION PROGRAMME

#### RIQASNet - ELECTRONIC CORRESPONDENCE

Participation on RIQAS requires access to RIQASNet, a web-based online method for result entry, viewing of released reports and addition or change of assay details. In addition, PDF reports can be e-mailed to up to 3 e-mail addresses. Internet access and login details are required for RIQASNet. A login will be supplied by RIQAS based on "e-mail address 1" below. It is also possible to receive a csy file containing the information found on the summary page of the routine report.

| I wish to receive a summary csv file (csv files must be sent to the same email addresses as the PDF reports) | FOR RIQAS USE ONLY RIQASNet No      |  |
|--|-------------------------------------|--|
|  | Date added: By:                     |  |
|  | PDF copies set to csv copies set to |  |

| Timilary Contact email for Micholieth Dr. reports/summary CSV mes (Flease write in Capital letters only) |  |  |  |  |  |
|--|--|--|--|--|--|
| E-mail address 1:  |  |  |  |  |  |
| E-mail addresses for additional PDF reports/summary csv files  |  |  |  |  |  |
| E-mail address 2:  |  |  |  |  |  |
| E-mail address 3:  |  |  |  |  |  |

Primary Contact amail for PIOASNot/PDE reports/summary say files (Please write in capital letters only)

Customer Declaration: By submitting this enrolment document to RIQAS, either directly or via my local Randox representative, I, (the customer of RIQAS) confirm that:

- 1) I have read and understood the RIQAS policies stated in the most recent Method Questionnaire associated with this programme.
- 2) I understand that the submission of this enrolment document to RIQAS marks the beginning of an on-going agreement, and I will be automatically enrolled in subsequent cycles of this programme until RIQAS receives written confirmation of my cancellation. This should be received by RIQAS 12 weeks prior to the month in which the cycle starts.
- 3) I understand that I must inform RIQAS of any changes to my contact details, assay details or contract status
- 4) I authorise Randox Laboratories Ltd. to send communication related to the products and service provided to the e-mail or postal addresses stated on this document
- 5) I understand that I am permitted to request disclosure of, change or erase personal details held by Randox Laboratories Ltd. at any

## REGISTRATION OF ASSAY DETAILS

It is possible to inform RIQAS of your chosen parameters and assay details by

- 1) Completing the 'REGISTRATION OF ASSAY DETAILS' on the following pages **OR**
- 2) Adding your own assay details using RIQASNet

Please select one of the following options

I wish to add my own assay details via RIQASNet once I have received my username, password and Lab Reference Number from RIQAS (You do not need to complete the 'REGISTRATION OF ASSAY DETAILS' section of this document) I wish to inform RIQAS of my assay details using this enrolment document

(please complete all remaining pages of the 'REGISTRATION OF ASSAY DETAILS' section)

For any further queries, please contact your local Randox office, Sales Representative or RIQAS directly.

Please contact RIQAS at

+44 (0) 28 9445 4399 Tel· mail@rigas.com F-Mail: RIQAS Scheme Co-ordinator: Sally Picton

RANDOX LABORATORIES LTD., 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

THIS PROGRAMME IS ACCREDITED BY UKAS TO ISO/IEC 17043:2010



0010

| п | ah  | Po    | ferei | 100   | Nı  | ım | har   |
|---|-----|-------|-------|-------|-----|----|-------|
| _ | au. | K (-) | ıerei | 11:12 | 141 |    | . 161 |

### **RIQAS COAGULATION PROGRAMME**

### **REGISTRATION OF ASSAY DETAILS**

# ONLY COMPLETE THIS SECTION IF YOU DO NOT INTEND TO REGISTER YOUR METHODS VIA RIQASNET

Please indicate your requirements by ✓ or by writing in the boxes below. Current participants should complete the document only for method changes.

This programme is not suitable for use with the ITC Hemochron Signature or Roche Coaguchek Instruments.

| ANALYTE                    | METHOD CODE | INSTRUMENT     | REAGENT | SI UNITS 🗸           | OTHER UNITS |
|----------------------------|-------------|----------------|---------|----------------------|-------------|
| FACTOR II ACTIVITY         |             |                |         | %                    | N/A         |
| FACTOR V ACTIVITY          |             |                |         | %                    | N/A         |
| FACTOR VII ACTIVITY        |             |                |         | %                    | N/A         |
| FACTOR VIII ACTIVITY       |             |                | ] []    | %                    | N/A         |
| FACTOR IX ACTIVITY         |             |                |         | %                    | N/A         |
| FACTOR X ACTIVITY          |             |                |         | %                    | N/A         |
| FACTOR XI ACTIVITY         |             |                |         | %                    | N/A         |
| FACTOR XII ACTIVITY        |             |                |         | %                    | N/A         |
| D-DIMER (PILOT)            |             |                |         | ug/l                 |             |
| KIT NAME/ CATALOGUE NUMBER |             | KIT LOT NUMBER |         | CONVERSION<br>FACTOR |             |
| FIBRINOGEN                 |             |                |         | g/I                  |             |
| PLASMINOGEN ACTIVITY       |             |                |         | %                    | N/A         |
| ANTITHROMBIN III ACTIVITY  |             |                |         | %                    | N/A         |
| PROTEIN C ACTIVITY         |             |                |         | %                    | N/A         |
| PROTEIN S ACTIVITY         |             |                |         | %                    | N/A         |
| aPTT AS A RATIO            |             |                |         | Ratio                | N/A         |
| aPTT IN SECONDS            |             |                |         | s                    | N/A         |

| 1 - 1. | D - (     | NI.    |
|--------|-----------|--------|
| Lab.   | Reference | Number |

# RIQAS COAGULATION PROGRAMME

#### **REGISTRATION OF ASSAY DETAILS**

ONLY COMPLETE THIS SECTION IF YOU DO NOT INTEND TO REGISTER YOUR METHODS VIA RIQASNET

Please indicate your requirements by ✓ or by writing in the boxes below. Current participants should complete the document only for method changes.

This programme is not suitable for use with the ITC Hemochron Signature or Roche Coaguchek Instruments.

| ANALYTE                     | METHOD CODE          | INSTRUMENT       | REAGENT         | SI UNITS 🗸 | OTHER UNITS |
|-----------------------------|----------------------|------------------|-----------------|------------|-------------|
| PT AS AN INR                |                      |                  |                 | INR        | N/A         |
| PT ACTIVITY                 |                      |                  |                 | %          | N/A         |
| PT AS A RATIO               |                      |                  |                 | Ratio      | N/A         |
| PT IN SECONDS               |                      |                  |                 | s          | N/A         |
| THROMBIN TIME               |                      |                  |                 | s          | N/A         |
| Please use this space to de | scribe "other" metho | ods, instruments | s and reagents. |            |             |
|                             |                      |                  |                 |            |             |

<u>PLEASE NOTE:</u> PT may be registered as seconds, % activity, ratio or INR. Registration of all of these will count as one analyte. aPTT may be registered as seconds or ratio. Registration of both will count as one analyte <u>PLEASE NOTE</u> Some users of ACL TOP instruments when used in combination with Hemosil Synthasil reagents may be unable to attain a clot with extended read time samples.